Background
==========

Chronic obstructive pulmonary disease (COPD) is highly prevalent and a leading cause of morbidity and mortality worldwide. Both social and economic burden continue to rise.[@b1-copd-12-2629] It has become widely accepted that the degree of airflow limitation is insufficient to estimate the severity and heterogeneity of COPD. Symptoms, exacerbations and comorbidities are well-established determinants.[@b2-copd-12-2629] Furthermore, there is growing interest in phenotyping the disease not only based on clinical characteristics but also on genetic, molecular and cellular parameters.[@b3-copd-12-2629],[@b4-copd-12-2629] By differentiating phenotypes, a more personalized and effective therapy might be achieved for subgroups of patients.

Jamieson et al[@b5-copd-12-2629] demonstrated that COPD patients with allergic sensitization experience more symptoms and exacerbations. Although hypersensitivity to *Aspergillus fumigatus* (*A fum*) was not measured here, two other studies have reported on the higher prevalence of *A fum* sensitization in COPD and its association with worse lung function.[@b6-copd-12-2629],[@b7-copd-12-2629] Sensitization is defined by the presence of allergen-specific IgE, which is routinely measured by skin prick test or in vitro immunoassay. In general, a crude extract of *A fum* is used, although purified or recombinant antigens of *A fum* are more specific.[@b8-copd-12-2629] Different studies suggest a role for these recombinant antigens in distinguishing patients with and without allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) and asthma.[@b9-copd-12-2629],[@b10-copd-12-2629] Whether *A fum* recombinant antigens are also of interest in other lung diseases such as COPD is not known.

COPD--bronchiectasis overlap syndrome is a potential clinical phenotype.[@b11-copd-12-2629] Prevalence varies greatly depending on the definition and methodology. Recent literature shows that bronchiectasis is clinically important[@b12-copd-12-2629]--[@b14-copd-12-2629] and composes an independent risk factor for mortality in COPD.[@b14-copd-12-2629]--[@b16-copd-12-2629] Moreover, diagnosis of bronchiectasis in COPD has an impact on therapeutic considerations such as the safety of inhaled corticosteroids, the need for inhaled antibiotics or maintenance therapy with azithromycin and the antimicrobial management of exacerbations. At present, the pathogenesis of non-CF bronchiectasis is explained by a vicious circle in which inflammation causes structural damage and impaired mucus clearance, which in turn promotes bacterial colonization and infection, again resulting in more inflammation.[@b17-copd-12-2629] The triggers for the development of bronchiectasis in COPD are not known. Given the multiple links between *Aspergillus* species and bronchiectasis,[@b18-copd-12-2629] we hypothesize that *A fum* may play an important role in the development of COPD-related bronchiectasis. As *A fum* sensitization and bronchiectasis may have a common link through suppression of the vitamin D signaling pathway,[@b19-copd-12-2629]--[@b21-copd-12-2629] we also speculate that vitamin D deficiency, which is frequently observed in COPD and bronchiectasis,[@b22-copd-12-2629],[@b23-copd-12-2629] may also contribute to *A fum* sensitization.

We performed an observational study in a COPD cohort and a smoking control group recruited from the outpatient clinic of the University Hospitals of Leuven. We explored if *A fum* sensitization was more prevalent in COPD patients versus controls by measuring IgE against the crude *A fum* extract and five commercially available *A fum* recombinant antigens. We hypothesized that *A fum*-sensitized COPD patients have different clinical characteristics, lower vitamin D serum levels and more bronchiectasis compared to COPD patients without *A fum* sensitization.

Methods
=======

Study design and subjects
-------------------------

In this observational study, subjects were retrospectively selected from the Leuven COPD cohort, a DNA, plasma and serum bank of a clinical-based COPD population and controls (NCT00858520). Inclusion criteria were an age of ≥50 years and a smoking history of ≥10 pack-years. A recent diagnosis of cancer, respiratory disorders other than COPD, major thoracic surgery and solid organ transplantation were exclusion criteria. Medical history, clinical parameters, therapy and the modified Medical Research Council (mMRC) breathlessness scale[@b24-copd-12-2629] were surveyed. Exacerbations were defined as acute events with worsening of respiratory symptoms that were beyond normal day-to-day variations and led to a change in medication.[@b2-copd-12-2629] The number of exacerbations in the year prior to inclusion was recorded. The combined assessment as proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) was used to stage the severity of COPD: breathlessness (mMRC) and exacerbation history were used to subdivide COPD patients into four stages; A, B, C and D.[@b2-copd-12-2629] The study was approved by the local ethics committee (Medical Ethical Board of the University Hospitals Leuven, Belgium -- ML11081), and all patients provided written informed consent. We selected 300 patients with an established diagnosis of COPD based on a post-bronchodilator forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) ratio \<0.7, who were included between October 2007 and September 2013. Selection of our study patients was based on Caucasian race, the availability of complete pulmonary function data and 1 mm thin-sliced computed tomography (CT) imaging of the thorax. The control group consisted of 50 (ex-) smokers with a post-bronchodilator FEV~1~/FVC ratio \>0.7, who were enrolled in a lung cancer screening trial (NELSON, ISRCTN63545820) between October 2007 and October 2009.[@b25-copd-12-2629]

Pulmonary function
------------------

Post-bronchodilator spirometry was measured at the time of recruitment using a standardized equipment (Sensormedics Whole Body Plethysmograph; Viasys Healthcare, Vilvoorde, Belgium), according to the American Thoracic Society/European Respiratory Society guidelines.[@b26-copd-12-2629] Diffusion capacity was measured by the single-breath carbon monoxide gas transfer method.[@b27-copd-12-2629] Results are reported as percentages predicted of reference values. COPD was diagnosed based on a post-bronchodilator FEV~1~/FVC ratio of \<0.7, and the post-bronchodilator FEV~1~ was used to classify patients according to the GOLD classification.[@b2-copd-12-2629]

CT images
---------

All subjects had a CT of the thorax within 1 year of enrollment. CT scans were taken for a variety of indications, which resulted in the use of different protocols in the COPD group. Nevertheless, only patients with slices of 1 mm were included in this study. Subjects in the control group were all scanned according to the same protocol as described before.[@b25-copd-12-2629] Airway dilatation was determined based on Naidich's descriptions: bronchoarterial ratio \>1, lack of tapering, presence of bronchus within 1 cm of costal pleura or abutting the mediastinal pleura.[@b28-copd-12-2629] All scans were blinded to the other data and scored for bronchiectasis using the modified Reiff score. This score ranges from 0 to 18 by assessing the number of involved lobes (the lingula considered separately) and the degree of bronchodilation (1= tubular, 2= varicose and 3= cystic).[@b29-copd-12-2629] A score of ≥2 was considered clinically relevant because minor bronchial dilatation is also described in healthy individuals.[@b30-copd-12-2629]

Blood analysis
--------------

Plasma was collected in cryotubes and stored at −80°C. Total IgE, IgE against *A fum* extract and against *A fum* recombinant antigens f1--f4 and f6 and *A fum* IgG were determined by ImmunoCAP fluoroenzyme immunoassay using an ImmunoCAP 1000 instrument (Phadia AB, Uppsala, Sweden). A cutoff of 114 kU/L was used for total IgE,[@b31-copd-12-2629] and specific IgE values \>0.35 kU/L were considered positive. We present the specific IgE results as proportions rather than absolute values due to the detection limit and the clinical relevance. 25-Hydroxy-vitamin D was measured using radioimmunoassay (RIA; DiaSorin, Brussels, Belgium) with results expressed in micrograms per liter.

Sputum
------

In the COPD group, the presence of potential pathogenic microorganisms (PPM) in historical sputum cultures was assessed from laboratory reports. All sputum cultures that were performed in our hospital since 2002 were evaluated. These sputum samples were mainly collected during bronchitis or exacerbation episodes. We registered if they ever had PPM cultured, and if so, which different species were found. All cultures were performed according to the standard protocol of our hospital. In brief, 10 μL of sputum sample was inoculated on four different agars: blood agar, *Haemophilus*-specific agar, mannitol salt agar and MacConkey agar. These were cultured for 2 days.

Statistical analysis
--------------------

Statistical analysis was performed with GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA) and SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). Normality was tested by the Shapiro--Wilk test; none of the continuous variables were normally distributed. Univariate comparisons between groups were performed by Wilcoxon rank-sum test and presented as median ± interquartile range (IQR). Proportions of discrete variables were compared with *χ*^2^ test and presented as absolute numbers and percentages. We built a multivariate logistic regression model to study the association between sensitization to *A fum* recombinant f1 (rAsp f1) or *A fum* recombinant f3 (rAsp f3) and bronchiectasis in COPD. After performing bivariable logistic regression models with modified Reiff score ≥2 as exposure, potential confounders of the association between sensitization and the presence of bronchiectasis were included in the final model if they 1) changed the estimate of the multivariable model ≥10% or 2) the variable was significantly associated with the presence of bronchiectasis. *P*-values \<0.05 were considered significant in all analyses.

Results
=======

Study group characteristics
---------------------------

A total of 350 subjects were included in this study: 300 patients with COPD and 50 (ex-) smoking controls. There was no difference in gender. Patients in the COPD group were older, smoked more and had a lower mean body mass index (BMI) than controls ([Table 1](#t1-copd-12-2629){ref-type="table"}). The COPD group had a median FEV~1~ of 43% predicted and a median diffusion capacity of 46% predicted. The majority of COPD patients were staged in GOLD classes 2 and 3 or groups B and D.[@b32-copd-12-2629] In vitamin D non-supplemented COPD patients (n=240), a significantly lower median vitamin D level was observed compared to the control group (17.3 versus 28.5 μg/L, *P*\<0.0001). The proportion of subjects with bronchiectasis was higher in the COPD group compared to controls (33% versus 10%, *P*=0.0010). More detailed information about the study groups is given in [Table 1](#t1-copd-12-2629){ref-type="table"}.

Total IgE and *A fum*-specific antibodies
-----------------------------------------

Total IgE, *A fum*-specific IgE against the crude extract and the recombinants and *A fum*-specific IgG were measured to determine antibody production against *A fum*. Details of these results are given in [Table 2](#t2-copd-12-2629){ref-type="table"}. There was a tendency to higher total IgE levels and more prevalent IgE against *A fum* extract in COPD patients compared to controls ([Figure 1A and B](#f1-copd-12-2629){ref-type="fig"}). If recombinant antigens were considered, significantly more COPD patients than controls had IgE against rAsp f1 (12% versus 2%, *P*=0.0332; [Figure 1B](#f1-copd-12-2629){ref-type="fig"}). Sensitization to *A fum* extract and rAsp f1 occurred in different patients: out of 50 patients sensitized to one of these two allergens, only 17 patients developed IgE antibodies \>0.35 kU/L against both *A fum* extract and rAsp f1 ([Table 3](#t3-copd-12-2629){ref-type="table"}). IgEs against *A fum* recombinant f2 (rAsp f2), *A fum* recombinant f4 (rAsp f4) and *A fum* recombinant f6 (rAsp f6) were only rarely present in both groups, while there was no significant difference in IgE against rAsp f3 ([Figure 1B](#f1-copd-12-2629){ref-type="fig"}). The difference in sensitization to at least one of the tested allergens was statistically significant: 55 (18.3%) COPD patients versus two (4%) controls, *P*=0.0110 ([Figure 1B](#f1-copd-12-2629){ref-type="fig"}). Furthermore, COPD patients had a higher median level of *A fum* IgG (31 versus 20.7 mg/L, *P*=0.0473; [Figure 1C](#f1-copd-12-2629){ref-type="fig"}).

Differences between sensitized and non-sensitized COPD patients
---------------------------------------------------------------

Clinical and demographic characteristics were compared between 55 *A fum*-sensitized COPD patients and 245 *A fum*-non-sensitized COPD patients. In the sensitized group, the proportion of men was significantly higher (83.6% versus 69%, *P*=0.0293). There was no difference in age, BMI, smoking history and use of inhaled corticosteroids. Furthermore, lung functional variables and GOLD stages were not different and sensitized patients did not experience more exacerbations compared to non-sensitized patients. Vitamin D levels were comparable in the sensitized versus non-sensitized COPD patients (16.2 versus 18.1 ng/mL, *P*=0.2057). However, median values of specific *A fum* IgG were higher in *A fum*-sensitized patients (43.2 versus 27.7 mg/L, *P*\<0.0001), who also had significantly more bronchiectasis compared to non-sensitized patients (45.5% versus 30.2%, *P*=0.0297). Data are presented in [Table 4](#t4-copd-12-2629){ref-type="table"}.

Interestingly, bronchiectasis was only detected in patients with sensitization to recombinants. None of the nine patients who were only sensitized to the crude extract -- and therefore not to any of the recombinant allergens -- had bronchiectasis. In contrast, patients with IgE against rAsp f1, and especially against rAsp f3, had significantly more bronchiectasis than patients without sensitization to these allergens ([Table 5](#t5-copd-12-2629){ref-type="table"}).

Results of sputum cultures were available in 197 patients. The median number of sputum samples per patient was not different between groups (4 \[IQR 2--6\] in sensitized patients and 3 \[IQR 1--5\] in non-sensitized patients, *P*=0.0692). PPM were significantly more prevalent in *A fum*-sensitized versus *A fum*-non-sensitized patients (76.9% versus 59.5%, *P*=0.0436; [Table 4](#t4-copd-12-2629){ref-type="table"}). Sputum cultures showed no difference in the presence of typical COPD pathogens like *Streptococcus pneumonia*, *Haemophilus influenza* and *Moraxella catarrhalis*. In contrast, *Pseudomonas aeruginosa* and *Serratia marcescens* were more common in sputum cultures of *A fum*-sensitized patients ([Figure 2](#f2-copd-12-2629){ref-type="fig"}).

Multivariate analysis with logistic regression showed a significant association between bronchiectasis, sensitization to rAsp f1 or rAsp f3 (*P*=0.0030) and age in COPD, independent of gender, BMI, diffusion capacity and presence of ≥2 exacerbations/year ([Table 6](#t6-copd-12-2629){ref-type="table"}). This significant association between rAsp f1 or rAsp f3 sensitization and bronchiectasis was confirmed with the same model in the subgroup of patients with sputum samples (n=197, *P*=0.0021), additionally corrected for the presence of PPM ([Table 6](#t6-copd-12-2629){ref-type="table"}).

Discussion
==========

This study shows that sensitization to *A fum* occurs more frequently in COPD patients compared to smoking controls, particularly when rAsp f1 is taken into account. *A fum* IgG levels are also significantly higher in the COPD group. *A fum*-sensitized COPD patients are more often male, with more proteobacteria in previous cultures, and depict a higher risk for bronchiectasis if sensitized to rAsp f1 or rAsp f3. Despite considerably lower vitamin D levels in COPD patients compared to controls, we did not find any relation with sensitization to *A fum* or bronchiectasis.

In our cohort, 34.3% of COPD patients had increased levels of total IgE compared to 22% in the control group. The higher prevalence of increased total IgE (47.3%) reported in another COPD cohort[@b7-copd-12-2629] may be explained by demographical differences, variable inclusion criteria and the use of a lower cutoff for positivity. In terms of sensitization to *A fum*, we found an 18.3% prevalence in COPD when taking crude extract and recombinant antigens into account. These results are in line with previously reported data of prevalence between 8.5% and 16%.[@b6-copd-12-2629],[@b7-copd-12-2629],[@b33-copd-12-2629],[@b34-copd-12-2629] As these studies are lacking an appropriate control group, our data clearly establish that sensitization to *A fum* is more common in COPD. We are aware of the younger age in our control group, but a median age difference of only 5 years seems insufficient to explain the higher rate of sensitization in COPD. The lack of skin prick tests is a limitation of our study because of a potential discordance between in vitro tests and skin prick tests to diagnose *A fum* sensitization.[@b35-copd-12-2629]

Bafadhel et al[@b6-copd-12-2629] showed an association between sensitization and lower FEV~1~ in COPD. Although our sample size was twice as large, we could not observe any relationship with FEV~1~, diffusion capacity, exacerbations or GOLD stages. A more pronounced male pre-dominance in the sensitized group may seem surprising, but has been described before.[@b36-copd-12-2629],[@b37-copd-12-2629] Cigarette smoke exposure is known to facilitate development of sensitization, however we found no difference in pack-years and current smoking between *A fum* sensitized and non-sensitized COPD patients. This is in contrast to a recent paper about bidi smokers where current smoking seemed a risk factor for *A fum* sensitization, irrespective of the presence of COPD.[@b34-copd-12-2629] Despite similar disease severity, bronchiectasis was significantly more frequent in sensitized patients, particularly when sensitized to rAsp f1 or rAsp f3 (50% or 60% prevalence, respectively). Moreover, multivariate analysis showed that the associated risk for bronchiectasis was independent of gender, age, BMI, diffusion capacity, frequent exacerbations and presence of PPM. Together, these observations support the hypothesis that *A fum* hypersensitivity might contribute to the development of bronchiectasis in COPD. Based on our results, we are not able to attribute causality. Furthermore, we realize that the association exists in two directions since the presence of bronchiectasis and COPD is a risk factor for colonization with *A fum* due to reduced mucociliary clearance and therapy with (inhaled) corticosteroids, antibiotics, etc. Nevertheless, some previous papers also suggested *A fum* as a causal factor for bronchiectasis. Clinically, colonization by *A fum* was associated with severity of bronchiectasis[@b38-copd-12-2629] and development of bronchiolitis obliterans syndrome after lung transplantation.[@b39-copd-12-2629] Furthermore, *A fum* sensitization was associated with bronchiectasis, irrespective of ABPA in asthma[@b40-copd-12-2629] and total IgE, which may represent an indirect marker of sensitization, seemed a risk factor for bronchiectasis in COPD patients.[@b41-copd-12-2629] From a mechanistic perspective, *Aspergillus* proteases play an important role. The serine protease activity of *A fum* stimulates MUC5AC, resulting in more mucus production by epithelial cells,[@b42-copd-12-2629] and *A fum* allergen proteases Asp f3 and Asp f15 have been shown to be responsible for the stimulation of the Th2 pathway and airway remodeling in a murine model.[@b43-copd-12-2629]

We could not measure blood eosinophils on the frozen blood samples, and therefore, we could not fulfill criteria for ABPA in this cohort.[@b44-copd-12-2629] In a recent paper, *A fum* IgG \>27 mg/L was used in a cohort of sensitized asthma patients to distinguish patients having ABPA from patients without ABPA.[@b45-copd-12-2629] This cutoff seems inappropriate in our *A fum*-sensitized COPD patients because the median *A fum* IgG value in our sensitized group was 43.2 mg/L. This could be explained by the fact that specific IgG is dependent on region, exposure and underlying disease. The higher levels of *A fum*-specific IgG, as a measure of exposure, may be due to reduced mucociliary function and reduced *A fum* clearance by innate immune cells in COPD patients versus controls.[@b46-copd-12-2629] This reduced clearance of fungal allergens may facilitate sensitization.

Next to the higher prevalence of bronchiectasis, more *A fum*-sensitized COPD patients had *P. aeruginosa* and *S. marcescens* present in their sputum compared to *A fum*-non-sensitized COPD patients. This finding further emphasizes the clinical relevance of our results since these pathogens may play a role in exacerbations and can become multidrug resistant. We did not report on culture results of *A fum* because the specific growth medium (Sabouraud) was only used on clinical indication. Moreover, sensitivity of culture for *A fum* is low and other detection methods such as polymerase chain reaction (PCR) may better reflect the presence of *A fum* in the airways.[@b47-copd-12-2629] Further prospective studies are therefore needed to explore the relationship between *A fum* colonization, sensitization and bronchiectasis. In line with these unknowns is the potential role of *A fum* on vitamin D receptor downregulation[@b20-copd-12-2629] as well as the effect of vitamin D deficiency on *A fum* sensitization[@b19-copd-12-2629],[@b21-copd-12-2629] and disease severity in bronchiectasis.[@b22-copd-12-2629] Our results did not show any obvious relationship, but it is clear that we cannot rule out a role of vitamin D deficiency based on this cross-sectional analysis with a relatively small sample size.

We are the first to report data on IgE against recombinant *A fum* allergens in COPD. rAsp f1 is a major and species-specific allergen of *A fum*, which in contrast to *A fum* extract shows no cross-reactivity with proteins of other species.[@b8-copd-12-2629] Exposure to rAsp f1 only occurs during fungal growth, which makes rAsp f1 a reliable and relevant antigen.[@b48-copd-12-2629] Although testing with the crude extract is assumed to be more sensitive than testing with the recombinants, we showed a higher prevalence of sensitization to rAsp f1 compared to the crude extract. This finding questions the reliability of the crude extract to diagnose *A fum* sensitization and emphasizes its known limitations such as cross-reactivity, lability and lack of standardization. However, it remains unclear why sensitization to rAsp f2 and rAsp f3 (other major allergens of *A fum*) was less frequently detected. Several reasons could explain why bronchiectasis was not present in the patients only sensitized against the crude *A fum* extract. The nine patients only sensitized to the crude *A fum* extract may be false positive due to cross-reactivity. On the other hand, specific allergens may be required to trigger pathways that contribute to bronchiectasis development, although controversial in ABPA.[@b10-copd-12-2629],[@b49-copd-12-2629] The role of different *A fum* allergens in the pathogenesis of ABPA and bronchiectasis is far from understood, and \>25 distinct *A fum* allergens have been identified.

The prevalence of bronchiectasis in our cohort (33%) lies within the wide range reported in other studies (4%--60%).[@b15-copd-12-2629],[@b50-copd-12-2629],[@b51-copd-12-2629] Although there is no specific radiologic scoring system validated for bronchiectasis in COPD, the modified Reiff score, which we applied, has been used in several studies.[@b29-copd-12-2629],[@b52-copd-12-2629],[@b53-copd-12-2629] Nevertheless, overestimation of bronchiectasis in COPD is possible since limited bronchiectasis is seen on high-resolution CT scans of healthy individuals and is also related to lung aging.[@b30-copd-12-2629],[@b54-copd-12-2629] We tried to avoid overestimation by considering only a modified Reiff score of ≥2 as meaningful and showed that the prevalence of bronchiectasis was at least higher in our patient cohort than in the controls.

Conclusion
==========

The results show a high prevalence of *A fum* sensitization in COPD patients and highlight a potential role of rAsp f1 and rAsp f3 in COPD-related bronchiectasis. Because of the retrospective, observational design of this study, we were not able to demonstrate a causal relationship. Nevertheless, this is the first report about the association between *A fum* sensitization, including five recombinant antigens, and bronchiectasis in COPD. An association between *A fum* sensitization and vitamin D deficiency was not found. The search for underlying mechanisms in the development of bronchiectasis in COPD is relevant, since the presence of bronchiectasis in COPD influences management and prognosis of the disease. Prospective, longitudinal studies are needed to prove causality and to allow speculation about preventive interventions.
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![Total IgE and *A fum*-specific antibodies in patients with COPD versus controls.\
**Notes:** Antibody levels were measured in plasma by ImmunoCAP fluoroenzyme immunoassay using an ImmunoCAP 1000 instrument (Phadia AB, Uppsala, Sweden). (**A**) Median values of total IgE. No significant difference between controls and COPD, *P*=0.3068. (**B**) Proportions of subjects with IgE against different *A fum* allergens: extract of *A fum*, *A fum* recombinant f1 (rAsp f1), *A fum* recombinant f2 (rAsp f2), *A fum* recombinant f3 (rAsp f3), *A fum* recombinant f4 (rAsp f4) and *A fum* recombinant f6 (rAsp f6). Total shows the proportion of participants sensitized against at least one of the tested allergens (\**P*\<0.05). (**C**) Median values of *A fum*-specific IgG. Difference between COPD and control was significant (\*\**P*=0.0473).\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; *A fum*, *Aspergillus fumigatus*; rAsp f1, *A fum* recombinant f1; rAsp f2, *A fum* recombinant f2; rAsp f3, *A fum* recombinant f3; rAsp f4, *A fum* recombinant f4; rAsp f6, *A fum* recombinant f6.](copd-12-2629Fig1){#f1-copd-12-2629}

![Potential pathogenic microorganisms present in sputum samples of COPD patients by *A fum* sensitization status.\
**Notes:** Occurrence of different species in sputum cultures. \**P*\<0.05.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; *A fum*, *Aspergillus fumigatus*; *MRSA*, methicillin-resistant *Staphylococcus aureus*.](copd-12-2629Fig2){#f2-copd-12-2629}

###### 

Study group characteristics

  Characteristic                Control             COPD                                                            *P*-values
  ----------------------------- ------------------- --------------------------------------------------------------- --------------
  Patients (n)                  50                  300                                                             
  Men (%)                       37 (74.0)           215 (71.7)                                                      0.7337
  Age, years                    62 (58--68)         67 (61--74)                                                     **0.0002**
  Pack-years                    35.5 (26.8--46.8)   48.9 (34.0--64.1)                                               **0.0001**
  Current smokers (%)           26 (52)             125 (42)                                                        0.1781
  BMI, kg/m^2^                  27.3 (23.9--29.4)   24.1 (20.7--27.5)                                               **0.0004**
  FEV~1~, L                     2.9 (2.4--3.4)      1.2 (0.9--1.6)                                                  NA
  FEV~1~, % pred                104 (92--111)       43 (34--58)                                                     NA
  DL,co, mmol/min/Kpa           7.5 (6.1--8.9)      3.8 (3.0--5.0)                                                  NA
  DL,co, % pred                 83 (78--94)         46 (36--58)                                                     NA
  GOLD 1/2/3/4, %               NA                  5.7/32.0/45.7/16.7                                              NA
  GOLD assessment A/B/C/D, %    NA                  4.0/21.3/5.3/69.3                                               NA
  Vitamin D, μg/L               28.5 (21.2--35.5)   17.3 (12.4--23.1)[a](#tfn2-copd-12-2629){ref-type="table-fn"}   \<**0.0001**
  Modified Reiff score ≥2 (%)   5 (10)              99 (33)                                                         **0.0010**

**Notes:** Data are presented as n, n (%), median (interquartile range) or %.

Based on 240 COPD patients after exclusion of subjects taking vitamin D supplements. *P*-values \<0.05 are shown in bold.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; % pred, percentage predicted; DL,co, diffusion capacity of the lung for carbon monoxide; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NA, not applicable.

###### 

Total IgE and *A fum*-specific antibodies

  Variables                                                             Control              COPD                 *P*-values
  --------------------------------------------------------------------- -------------------- -------------------- ------------
  Patients (n)                                                          50                   300                  
  Total IgE, kU/L                                                       42.5 (16.5--105.5)   52.0 (17.0--198.5)   0.3068
  Total IgE \>114, kU/L (%)                                             11 (22)              103 (34.3)           0.0849
  *A fum* extract IgE (%)                                               1 (2)                31 (10.3)            0.0584
  rAsp f1 IgE (%)                                                       1 (2)                36 (12)              **0.0332**
  rAsp f2 IgE (%)                                                       1 (2)                7 (2)                0.8839
  rAsp f3 IgE (%)                                                       1 (2)                20 (6.7)             0.1983
  rAsp f4 IgE (%)                                                       0 (0)                3 (1)                0.4776
  rAsp f6 IgE (%)                                                       0 (0)                4 (1.3)              0.4115
  Sensitized in total (%)[a](#tfn5-copd-12-2629){ref-type="table-fn"}   2 (4)                55 (18.3)            **0.0110**
  *A fum* IgG, mg/L                                                     20.7 (9.6--42.8)     31.0 (15.9--48.5)    **0.0473**

**Notes:** Data are presented as n, median (interquartile range) or n (%). *P*-values \<0.05 are shown in bold.

Sensitization to at least one of the *A fum* allergens including the extract.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; *A fum*, *Aspergillus fumigatus*; rAsp f1, *A fum* recombinant f1; rAsp f2, *A fum* recombinant f2; rAsp f3, *A fum* recombinant f3; rAsp f4, *A fum* recombinant f4; rAsp f6, *A fum* recombinant f6.

###### 

IgE against *A fum* extract and rAsp f1 in a contingency table

                                    rAsp f1 IgE present   rAsp f1 IgE absent   Row total
  --------------------------------- --------------------- -------------------- ------------
  ***A fum* extract IgE present**   17 (7.5)              14 (4.7)             31 (10.3)
  ***A fum* extract IgE absent**    19 (6.3)              250 (83.3)           269 (89.7)
  **Column total**                  36 (12.0)             264 (88.0)           300 (100)

**Note:** Data are presented as n (%).

**Abbreviations:** *A fum*, *Aspergillus fumigatus*; rAsp f1, *A fum* recombinant f1.

###### 

*A fum*-sensitized COPD patients versus *A fum*-non-sensitized COPD patients

  Characteristic                                                        COPD patients non-sensitized to *A fum*   COPD patients sensitized to *A fum*   *P*-values
  --------------------------------------------------------------------- ----------------------------------------- ------------------------------------- --------------
  Patients (%)                                                          245 (81.7)                                55 (18.3)                             
  Men (%)                                                               169 (69.0)                                46 (83.6)                             **0.0293**
  Age, years                                                            67 (61--74)                               68 (64--74)                           0.2767
  BMI, kg/m^2^                                                          24.4 (20.9--27.7)                         23.3 (19.7--26.9)                     0.0785
  Pack-years                                                            48.0 (33.5--63.8)                         52.5 (35.3--66.0)                     0.3518
  Current smoking (%)                                                   99 (40.6)                                 26 (47.3)                             0.3629
  ICS (%)                                                               197 (80.4)                                49 (89.1)                             0.1299
  FEV~1~, L                                                             1.18 (0.86--3.93)                         1.70 (0.83--2.86)                     0.7632
  FEV~1~, % pred                                                        43 (34--58)                               41 (33--56)                           0.4461
  DL,co, mmol/min/Kpa                                                   3.9 (3.0--9.6)                            3.6 (2.7--7.7)                        0.4038
  DL,co, % pred                                                         47 (37--59)                               42 (32--58)                           0.1618
  GOLD 1/2/3/4, %                                                       5.7/33.1/44.5/16.7                        5.5/27.3/50.9/16.4                    0.8291
  GOLD assessment A/B/C/D, %                                            3.7/22.5/4.9/69.0                         5.5/16.4/7.3/70.9                     0.6515
  ≥2 exacerbations/year (%)                                             102 (41.6)                                28 (50.9)                             0.2096
  Vitamin D, μg/L[a](#tfn10-copd-12-2629){ref-type="table-fn"}          18.1 (12.4--24.8)                         16.2 (12.4--21.2)                     0.2057
  Vitamin D ≤20 μg/L (%)[a](#tfn10-copd-12-2629){ref-type="table-fn"}   112 (56.9)                                30 (69.8)                             0.1185
  *A fum* IgG, mg/L                                                     27.7 (13.9--44.4)                         43.2 (27.0--66.0)                     \<**0.0001**
  Modified Reiff score ≥2 (%)                                           74 (30.2)                                 25 (45.5)                             **0.0297**
  Sputum PPM (%)[b](#tfn11-copd-12-2629){ref-type="table-fn"}           94 (59.5)                                 30 (76.9)                             **0.0436**

**Notes:** Data are presented as n (%), median (interquartile range) or %.

Based on 240 COPD patients after exclusion of subjects taking vitamin D supplements: 197 non-sensitized and 43 sensitized patients.

Based on 197 patients of whom sputum results were available: 158 non-sensitized and 39 sensitized patients. *P*-values \<0.05 are shown in bold.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; *A fum*, *Aspergillus fumigatus*; BMI, body mass index; ICS, inhaled corticosteroids; FEV~1~, forced expiratory volume in 1 second; % pred, percentage predicted; DL,co, diffusion capacity of the lung for carbon monoxide; GOLD, Global Initiative for Chronic Obstructive Lung Disease; PPM, potential pathogenic microorganisms.

###### 

*A fum* sensitization and bronchiectasis in COPD

  Variables                                        COPD patients (n)   Modified Reiff score ≥2 (%)   *P*-values
  ------------------------------------------------ ------------------- ----------------------------- ------------
  IgE *A fum* extract                              31                  12 (38.7)                     0.4752
  IgE *A fum* extract or rAsp f1--f4 and rAsp f6   55                  25 (45.5)                     **0.0297**
  IgE *A fum* extract without recombinants         9                   0 (0)                         
  IgE rAsp f1                                      36                  18 (50)                       **0.0208**
  IgE rAsp f3                                      20                  12 (60)                       **0.0079**

**Notes:** Data are presented as n and n (%). *P*-values \<0.05 are shown in bold.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; *A fum*, *Aspergillus fumigatus*; rAsp f1, *A fum* recombinant f1; rAsp f2, *A fum* recombinant f2; rAsp f3, *A fum* recombinant f3; rAsp f4, *A fum* recombinant f4; rAsp f6, *A fum* recombinant f6.

###### 

Association of bronchiectasis (modified Reiff score ≥2) and sensitization to rAsp f1 or rAsp f3 in COPD by a logistic regression model

  Variables                             In all COPD patients (n=300)   In COPD patients with sputum samples (n=197)                       
  ------------------------------------- ------------------------------ ---------------------------------------------- ------------------- ------------
  Sensitization to rAsp f1 or rAsp f3   2.8 (1.42--5.53)               **0.0030**                                     3.4 (1.56--7.48)    **0.0021**
  Gender                                1.5 (0.81--2.75)               0.1953                                         1.8 (0.82--4.04)    0.1424
  Age                                   1.0 (1.00--1.07)               **0.0349**                                     1.03 (0.99--1.07)   0.2064
  BMI                                   1.0 (0.91--1.01)               0.1198                                         0.96 (0.89--1.03)   0.2155
  DL,co, % pred                         1.0 (0.97--1.00)               0.1353                                         0.98 (0.96--1.01)   0.1572
  ≥2 exacerbations/year                 1.6 (0.97--2.72)               0.0642                                         2.11 (1.13--3.94)   **0.0188**
  PPM in sputum                         NA                                                                            0.68 (0.35--1.32)   0.2573

**Note:** *P*-values \<0.05 are shown in bold.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; rAsp f1, *A fum* recombinant f1; rAsp f3, *A fum* recombinant f3; OR, odds ratio; CI, confidence interval; BMI, body mass index; DL,co, diffusion capacity of the lung for carbon monoxide; % pred, percentage predicted; PPM, potential pathogenic microorganisms; NA, not applicable.
